Magnetic Resonance Imaging (MRI) Staging of Cervix Cancer

Trans Tasman Radiation Oncology Group (TROG) 04.02 - Prospective Study to Determine the Relationships Between Survival and International Federation of Gynecology and Obstetrics (FIGO) Stage, Tumour Volume and Corpus Invasion in relation to prognostic information in patients with Cervical Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12607000145404

Acronym

TROG 04.02

Enrollment

109

Registered

2007-02-26

Start date

2006-01-06

Completion date

2009-06-09

Last updated

2026-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The researchers propose that it may be corpus invasion, rather than tumour volume per se, which is one of the important determinants of ultimate outcome in cervix cancer. The aim of the proposed prospective, multicentre study, is to confirm the results of our retrospective studies, specifically that corpus invasion or tumour volume or both contribute important prognostic information over and above that provided by the currently used International Federation of Gynecology and Obstetrics (FIGO) staging system. A successful outcome would have important implications for the staging, and management as well as the biologic understanding of the behaviour of cervical cancer.

Interventions

Newly diagnosed cervical cancer patients will have key prognostic variables (FIGO stage, tumour diameter, corpus invasion etc) collected at baseline. The treatment received will be documented at the end of treatment and patients will then be followed for first relapse and survival. The duration will be 5 years.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Newly diagnosed, biopsy proven carcinoma of the uterine cervix.- Squamous cell, adenocarcinoma, adenosquamous or large cell carcinoma histology.- FIGO Stage Ib –IVa.- Maximum clinical tumour diameter recorded.- MRI done within 30 days prior to registration.- Intention to treat radically- Treatment not yet started.- Written informed consent.- Available for follow-up.

Exclusion criteria

Lymphoma, small cell carcinoma and melanoma histology.- Previous hysterectomy- Pregnancy- Prior malignancy excluding basal cell carcinoma (BCC) of the skin.

Outcome results